Camp4 Therapeutics Corporation (CAMP)

NASDAQ: CAMP · Real-Time Price · USD

7.01

+0.26 (3.85%)

At close: Dec 16, 2025, 4:00 PM EST

7.10

+0.09 (1.28%)

After-hours: Dec 16, 2025, 7:13 PM EST

Camp4 Therapeutics Employees

Camp4 Therapeutics had 55 employees as of December 31, 2024. The number of employees decreased by 9 or -14.06% compared to the previous year.

Employees

55

Change (1Y)

-9

Growth (1Y)

-14.06%

Revenue / Employee

$69,127

Profits / Employee

-$970,873

Market Cap

328.64M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	55	-9	-14.06%
Dec 31, 2023	64	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

CAMP News

4 days ago - CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
4 weeks ago - CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
5 weeks ago - CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights - GlobeNewsWire
2 months ago - CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01 - GlobeNewsWire
3 months ago - CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders - GlobeNewsWire
4 months ago - CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights - GlobeNewsWire
7 months ago - CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire
7 months ago - CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights - GlobeNewsWire